PBS knocks back rheumatology drug listings

A bid to ease PBS prescribing restrictions on the gout drug febuxostat  (Adenuric) was one of several disappointments for rheumatology drugs being assessed by the Pharmaceutical Benefits Advisory Committee.

An application for febuxostat’s  listing for chronic gout to be changed from ‘Authority Required’ to ‘Authority required (STREAMLINED)’ was rejected at the most recent meeting in July on the basis that the committee considered the current restriction remained appropriate to prevent the risk of prescribing behaviour outside of the current PBS